Clinical Trials Logo

Clinical Trial Summary

This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment. In this study phase, a traditional "3+3" trial design is employed for dose escalation.


Clinical Trial Description

The study plans to include CD19-positive relapsed/refractory B-cell tumor patients. After the screening period, peripheral blood mononuclear cell (PBMC) collection, and lymphocyte depletion pre-treatment period, subjects will receive a single infusion of anti-CD19-CAR-T cells. In addition to the baseline period, efficacy assessments will be conducted monthly for ALL subjects and at weeks 4, 12, 24, 36, and 48 post-treatment for NHL subjects, until disease progression (PD), relapse, change of treatment regimen, death, intolerable toxicity, at the discretion of the investigator, or voluntary withdrawal by the patient (whichever occurs first). Toxicity will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Safety of anti-CD19-CAR-T cell therapy will be evaluated through laboratory tests, 12-lead electrocardiograms, vital signs, physical examinations, etc. Blood samples will be collected from subjects to assess cellular pharmacokinetics and explore the effects of cellular drugs on ferritin, C-reactive protein, and related cytokines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06375161
Study type Interventional
Source Shanghai Tongji Hospital, Tongji University School of Medicine
Contact Aibin Liang
Phone +86 21 6611 1019
Email lab7182@tongji.edu.cn
Status Recruiting
Phase Early Phase 1
Start date December 11, 2023
Completion date December 10, 2039

See also
  Status Clinical Trial Phase
Recruiting NCT05995015 - 4SCAR19U T Cells Targeting B Cell Malignancies Phase 1
Recruiting NCT05436509 - CD19/79b Bi-specific CAR-T Cell Therapy Phase 1/Phase 2
Recruiting NCT05436496 - CD19/70 Bi-specific CAR-T Cell Therapy Phase 1/Phase 2
Recruiting NCT05432882 - CD19/22 Bi-specific CAR-T Cell Therapy Phase 1/Phase 2
Terminated NCT00672152 - A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation Phase 1
Recruiting NCT05618028 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets Phase 1